360 related articles for article (PubMed ID: 18574024)
1. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Argyriou AA; Iconomou G; Kalofonos HP
Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
[TBL] [Abstract][Full Text] [Related]
2. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Cavaletti G; Jakubowiak AJ
Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-induced peripheral neurotoxicity: an update.
Argyriou AA; Cavaletti G; Bruna J; Kyritsis AP; Kalofonos HP
Arch Toxicol; 2014 Sep; 88(9):1669-79. PubMed ID: 25069804
[TBL] [Abstract][Full Text] [Related]
4. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y; Lee SY; Kim I; Kwon JH; Yoon SS; Park S; Chung MH; Suh SY; Kim KS; Kim HS
Cancer Chemother Pharmacol; 2014 Sep; 74(3):653-7. PubMed ID: 25096796
[TBL] [Abstract][Full Text] [Related]
9. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Broyl A; Jongen JL; Sonneveld P
Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice.
Meregalli C; Carozzi VA; Sala B; Chiorazzi A; Canta A; Oggioni N; Rodriguez-Menendez V; Ballarini E; Ceresa C; Nicolini G; Crippa L; Orciani M; Cavaletti G; Marmiroli P
J Biol Regul Homeost Agents; 2015; 29(1):115-24. PubMed ID: 25864747
[TBL] [Abstract][Full Text] [Related]
11. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
12. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Cartoni C; Brunetti GA; Federico V; Efficace F; Grammatico S; Tendas A; Scaramucci L; Cupelli L; D'Elia GM; Truini A; Niscola P; Petrucci MT
Support Care Cancer; 2012 Oct; 20(10):2621-6. PubMed ID: 22699304
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Zhang LL; Wang YH; Shao ZH; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced severe autonomic neuropathy.
Stratogianni A; Tosch M; Schlemmer H; Weis J; Katona I; Isenmann S; Haensch CA
Clin Auton Res; 2012 Aug; 22(4):199-202. PubMed ID: 22532274
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Bao T; Goloubeva O; Pelser C; Porter N; Primrose J; Hester L; Sadowska M; Lapidus R; Medeiros M; Lao L; Dorsey SG; Badros AZ
Integr Cancer Ther; 2014 Sep; 13(5):396-404. PubMed ID: 24867959
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
Nasu S; Misawa S; Nakaseko C; Shibuya K; Isose S; Sekiguchi Y; Mitsuma S; Ohmori S; Iwai Y; Beppu M; Shimizu N; Ohwada C; Takeda Y; Fujimaki Y; Kuwabara S
Clin Neurophysiol; 2014 Feb; 125(2):381-7. PubMed ID: 23973385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
